Navigation Links
Oxidation defense in mosquitoes benefits malaria parasite

Scientists from two universities in Italy and Virginia Tech in the United States have determined the structure of a protein that is responsible for the production xanthurenic acid (XA) in Anopheles gambiae, the malaria carrying mosquitoes. XA plays a key role in the sexual reproduction of the malaria parasite (Plasmodium falciparum) in A. gambiae mosquitoes. Interfering with the formation of XA could be an avenue for development of drugs and insecticides to block malaria transmission. Millions of people worldwide are infected with malaria.

The research will be presented in the Proceedings of the National Academy of Science (PNAS) on-line as early as April 3 and in print April 11, 2006 ("Crystal structure of the Anopheles gambiae 3-hydroxykynurenine transaminase" by Franca Rossi, Silvia Garavaglia, and Giovanni Battista Giovenzana, of the DiSCAFF-Drug and Food Biotechnology Center at the University of Piemonte Orientale 'Amedeo Avogadro'; Bruno Arca' of the Department of Biological Structure and Function at the University of Napoli 'Federico II'; Jianyong Li of the Department of Biochemistry at Virginia Tech, and Menico Rizzi, also of the University of Piemonte Orientale).

The synthesis of XA is one of the biochemical defenses against oxidative stress resulting from 3-hydroxykynurenine (3-HK) accumulation in mosquitoes and possibly other species as well. "3-HK is oxidized easily under physiological condition, stimulating the production of reactive oxygen species, which can damage cells," said Li.

Mammals have various biochemical pathways of disposing of 3-HK, which mosquitoes lack. Research by Li's group at Virginia Tech on Aedes aegypti mosquitoes determined that "mosquitoes have developed an efficient strategy to prevent the accumulation of 3-HK by converting the chemically reactive 3-HK to the chemically stable XA via transaminase-mediated reactions," said Li.

The protein described in the PNAS article is responsible for this transf orming of 3-HK into XA in the malaria vector Anopheles gambiae, where XA also helps the malarial parasite reproduce. So stopping the oxidative defense could stop the parasite as well as make the insect a victim of oxidative stress.

Rizzi's group at the University of Piemonte Orientale focuses on the structural characterization of enzymes involved in tryptophan degradation in mosquitoes, which results in the synthesis of XA. "Deciphering the molecular architecture of each enzyme in this pathway will be used for the structure-based rational design of potent and highly selective inhibitors of potential interest as innovative antimalarial agents," said Rizzi

Li's group at Virginia Tech biochemically characterizes enzymes involved in conversion to XA, including trptophan, the initial precursor of the process.

The researchers have collaborated since 2003.

"The use of protein crystallography in combination with biochemical studies and medicinal chemistry, represents a highly multidisciplinary approach that could lead to the identification of novel agents for the treatment of malaria," said Rizzi.

The PNAS article describes what an International team of scientists learned about the structure of Anopheles gambiae 3-HK transaminase. The research will continue on the rational design of a small molecule that could be synthesized, and that would allow the malaria cycle to be interrupted, therefore representing a novel avenue for the treatment of malaria.


'"/>

Source:Virginia Tech


Related biology news :

1. Female sex hormones play a vital role in defense against sexually transmitted diseases
2. In the sea slugs defense against lobsters, confusion is key
3. Disease diagnosis, biodefense among UH chemical research projects
4. Comprehensive biodefense text published
5. Ancient immune defense mechanism is no match for HIV-1
6. Discovery could be key to bioterrorism defense
7. Variation in HIVs ability to disable host defenses contributes to rapid evolution
8. Scientists show that tick-borne flaviviruses use a novel mechanism to evade host defenses
9. Researchers uncover E. colis defense mechanism
10. Energy management in cells may hold key to cancer defense
11. Bacteria recognize antimicrobials, respond with counter-defenses
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... , Nov. 30, 2016  The Allen Institute ... Collection: the first publicly available collection of gene ... that target key cellular structures with unprecedented clarity. ... these powerful tools are a crucial first step ... better understand what makes human cells healthy and ...
(Date:11/30/2016)... and BEIJING , Nov. 30, 2016 ... provider of genomic services and solutions with cutting edge ... it has completed a USD $75 Million [515 Million ... Ltd.,s CMB International Capital Management ( Shenzhen ... Co., Ltd. ("SDIC Innovation") and Shanghai Sigma Square Investment ...
(Date:11/30/2016)... , Nov. 30, 2016   Merck , a ... has entered into a set of agreements with Evotec ... Merck,s collection of genetic reagents such as CRISPR and ... screening expertise offers an accelerated pathway to explore and ... with the identification of new targets, a process that ...
(Date:11/30/2016)... Research Triangle Park, NC (PRWEB) , ... November ... ... drug development company engaged in the development of a new orally administered treatment ... cognitive testing and neuroimaging results of a Phase 2a clinical trial of T3D-959 ...
Breaking Biology Technology: